Census Healthcare (SRTS) Q1 2026: CPT Code Change Drives 300% Payment Uplift, Accelerates Recurring Revenue Shift
Census Healthcare’s first quarter marked a pivotal shift as new CPT codes for superficial radiotherapy unlocked a 300% increase in per-fraction reimbursement, immediately transforming the adoption landscape and customer economics. The company is now executing a transition to a recurring revenue model, diversifying its customer base, and focusing on sustainable profitability, with early signals of pipeline momentum and improved commercial mix. Investors should track how recurring revenue and customer diversification play out as the new reimbursement environment matures through 2026.
Summary
- Reimbursement Structure Reset: New CPT codes sharply improved physician economics, catalyzing broader SRT adoption.
- Recurring Revenue Momentum: Shift to utilization-based and software-linked models is gaining traction across a more diverse customer set.
- Profitability Path: Management is signaling line-of-sight to full-year profitability as commercial execution ramps.
Business Overview
Census Healthcare develops and sells superficial radiotherapy (SRT) systems, which are non-invasive devices used primarily for the treatment of non-melanoma skin cancers. The company generates revenue through direct sales, leasing, and recurring utilization-based arrangements, including the Fair Deal Agreement (FDA, shared service model) and new software offerings like CensusLink. Key segments include direct equipment sales, recurring utilization revenue, and service/software income, with a growing focus on recurring streams as the installed base expands.
Performance Analysis
Q1 2026 results showcased the impact of Census Healthcare’s transition away from dependence on a single large customer, as revenue dropped sharply versus the prior year due to the absence of bulk sales to that customer. However, excluding that outsized customer, underlying revenue grew, reflecting a broader, more diversified customer base and a shift in product mix. The company shipped 14 SRT systems (10 direct sales, 4 placements/rentals), maintaining the prior quarter’s shipment pace despite the customer reset.
Gross margin compressed materially to 29.2% from 52.2% YoY, driven by a higher portion of international shipments (which carry lower average selling prices) and a greater mix of recurring revenue arrangements, where revenue is recognized over time. Operating expenses declined across general, sales, and R&D lines, reflecting tighter cost control and less need for lobbying after reimbursement clarity. Adjusted EBITDA loss widened as the business absorbs the transition, but the company ended the quarter with $18.3 million cash and no debt, providing runway for execution.
- Customer Concentration Reset: No sales to the historical largest customer, but pipeline strength and new customer adoption offset the gap.
- Recurring Revenue Inflection: FDA and rental placements now comprise a rising share of shipments, with treatment volumes up 8% YoY.
- Margin Headwind from Mix: Lower-margin international and recurring placements diluted gross margin, but are expected to become accretive as utilization ramps.
With the CPT code change now in effect, Census is positioned for sequential revenue growth and an improved quality of earnings as the year progresses, with a clear focus on recurring revenue penetration and commercial diversification.
Executive Commentary
"With the dedicated CPD codes for superficial radiotherapy now in effect as of January 1, We are now operating in a fundamentally different environment than ever before. We are tasked with the responsibility of helping our entire industry pivot to the new reality."
Joe Sardano, Chairman and Chief Executive Officer
"Importantly, excluding sales to that customer in the prior year period, revenue increased...demonstrating underlying growth driven by a broader mix of customers."
Javier Rampolla, Chief Financial Officer
Strategic Positioning
1. Reimbursement Clarity as Adoption Catalyst
The implementation of dedicated CPT codes for SRT has fundamentally shifted the adoption calculus for dermatology practices, moving SRT from a discretionary to a financially compelling option. The 300% increase in per-fraction reimbursement has been validated by payers, removing historic uncertainty and accelerating pipeline conversion. This change is enabling practices to breakeven with as little as two patients per month, with a growing share opting for outright purchase over shared service models.
2. Recurring Revenue and Software Monetization
Census is prioritizing recurring revenue growth through both utilization-based models and new software offerings. The Fair Deal Agreement and rental placements are expanding, with treatment volumes up 8% YoY. The launch of CensusLink, a workflow and documentation platform tied to radiation physics reimbursement, opens a new scalable recurring revenue stream that is exclusive to Census customers. Management expects recurring revenue to rise from its historical 10% of mix toward a larger share as software and service offerings mature.
3. Customer Base Diversification and Commercial Model Expansion
The company is actively broadening its customer base beyond large single buyers, targeting independent dermatology practices, hospital systems, and private equity-backed platforms. The launch of Census Healthcare Financial Services provides flexible financing, supporting higher conversion rates and reducing volatility. International markets, such as China, are contributing to shipment growth and offer attractive margin profiles due to lower servicing costs.
4. Operating Discipline and Profitability Focus
Cost containment has been prioritized, with reductions in lobbying, R&D, and trade show spend following the reimbursement win. The company’s strong cash position and no-debt balance sheet provide flexibility to invest in commercial expansion and product development while maintaining a clear path toward full-year profitability.
5. Education and Market Activation
Ongoing education of physicians and administrators around the new reimbursement environment is a key lever. High-yield dermatology conferences and targeted outreach are fueling pipeline growth, with management reporting record engagement and follow-up activity. As market understanding deepens, conversion rates are expected to accelerate through 2026.
Key Considerations
Census Healthcare’s first quarter marks a structural reset of its business model, with reimbursement certainty unlocking adoption and recurring revenue. The following factors are central to the company’s trajectory:
Key Considerations:
- Adoption Acceleration Signal: Physician and practice engagement is rising sharply post-CPT code, with conferences and demos translating into a robust pipeline.
- Recurring Revenue Ramp: FDA and software-linked models are expected to drive a larger share of future revenue, but require patience as pipeline converts and utilization builds.
- Customer Mix Evolution: Diversification away from a single large buyer is underway, but the pace and breadth of new customer adoption will determine revenue stability.
- Margin Recovery Path: Current margin compression reflects mix shift, but management expects margin improvement as recurring models scale and international mix stabilizes.
Risks
Execution risk remains around the pace of recurring revenue conversion, with delayed pipeline realization or slower-than-expected utilization potentially prolonging margin pressure. Competitive and regulatory risk is lower with exclusive CPT codes, but the market’s ultimate size and adoption rate are not yet fully proven. International expansion introduces currency and operational complexity. Patient and physician education remains a gating factor for accelerating adoption, and any setbacks could delay the profitability timeline.
Forward Outlook
For Q2 2026, Census guided to:
- Sequential revenue growth over Q1, driven by pipeline conversion and higher shipment volume
- Continued expansion of recurring revenue streams from FDA and CensusLink
For full-year 2026, management maintained its commitment to:
- Delivering improved financial performance each quarter with the objective of achieving full-year profitability
Management highlighted several factors that will shape results:
- Utilization ramping in FDA and rental placements as recurring revenue builds
- Margin improvement as product mix normalizes and software revenue grows
Takeaways
Census Healthcare’s Q1 signals a business model inflection, with reimbursement-driven adoption, recurring revenue momentum, and customer diversification setting the stage for a more predictable and profitable operation.
- Reimbursement Reset: The new CPT codes are driving a tangible step-change in SRT adoption economics, with clear signals of increased physician engagement and pipeline strength.
- Recurring Revenue Traction: The expansion of FDA, rental, and software-linked revenue streams is underway, but investors should track the rate of conversion and utilization as the key to sustainable margin recovery.
- Profitability Watch: Management’s confidence in sequential improvement and full-year profitability will be tested by the pace of recurring revenue build and customer diversification through 2026.
Conclusion
Census Healthcare’s Q1 2026 marks a structural transition as reimbursement clarity unlocks adoption and recurring revenue potential. The company’s ability to scale its new business model, diversify its customer base, and deliver on profitability targets will be the key investor watchpoints through the remainder of the year.
Industry Read-Through
The SRTS reimbursement-driven inflection provides a clear read-through for medtech and device companies reliant on procedural volume and insurance coverage. Dedicated CPT code wins can act as powerful catalysts, shifting adoption curves and driving recurring revenue opportunities tied to utilization and software. Customer concentration risk is a persistent theme in capital equipment models, and SRTS’s experience highlights the importance of commercial diversification and flexible financing. For peers in dermatology, oncology, and adjacent device markets, the rapid shift in physician economics and adoption logic underscores the value of proactive regulatory and market education strategies. As recurring revenue models become more prevalent, investors should scrutinize the mix, margin, and conversion dynamics that underpin long-term value creation.